MediWound Ltd.

NasdaqGM MDWD

MediWound Ltd. Return on Equity (ROE) for the year ending December 31, 2023: -21.26%

MediWound Ltd. Return on Equity (ROE) is -21.26% for the year ending December 31, 2023, a 88.16% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

MediWound Ltd. Return on Equity (ROE) for the year ending December 31, 2022 was -179.58%, a -160.72% change year over year.
MediWound Ltd. Return on Equity (ROE) for the year ending December 31, 2021 was 295.74%, a 324.00% change year over year.
MediWound Ltd. Return on Equity (ROE) for the year ending December 31, 2020 was -132.03%, a -638.65% change year over year.
MediWound Ltd. Return on Equity (ROE) for the year ending December 31, 2019 was 24.51%, a 308.05% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

NasdaqGM: MDWD

MediWound Ltd.

CEO	Mr. Ofer Gonen B.Sc.
IPO Date	March 20, 2014
Location	Israel
Headquarters	42 Hayarkon Street
Employees	100
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Key trends

Past 5 years